| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash provided by financing activities | 4,081 | 3,237 |
| Effect of foreign exchange rate changes on cash and cash equivalents | 13 | 25 |
| (decrease) / increase in cash and cash equivalents | -13,922 | 1,082 |
| Cash and cash equivalents at beginning of period | 36,330 | - |
| Cash and cash equivalents at end of period | 22,408 | - |
Arbutus Biopharma Corp (ABUS)
Arbutus Biopharma Corp (ABUS)